Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

SAIT301

Known as: Anti-C-met Monoclonal Antibody SAIT301 
A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background Samsung Advance Institute of Technology‐301 (SAIT301) is a human immunoglobulin G2 antibody that can specifically… 
  • table 1
  • figure 1
  • table 2
  • table 2
  • figure 2
2015
2015
The c-Met is frequently overexpressed and related to a worse prognosis in gastric carcinoma (GC). This study aimed to determine a… 
2015
2015
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a… 
2014
2014
Nasopharyngeal carcinoma (NPC) is a common malignant tumor with high invasive and metastatic potential. The hepatocyte growth… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2014
Highly Cited
2014
The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Met is a receptor tyrosine kinase that promotes cancer… 
2013
2013
The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer…